arrow
L

Luciane Sussuchi da Silva

barretos cancer hospital
H指数:13
被引数:559

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hybrid Dihydropyrimidinones Targeting AKT Signaling: Antitumor Activity in Hormone-Dependent 2D and 3D Cancer Models

靶向AKT信号通路的杂合二氢嘧啶二酮:在激素依赖性2D和3D癌症模型中的抗肿瘤活性

2025-11-150
OAAI
Feasibility of a ctDNA multigenic panel for non-small-cell lung cancer early detection and disease surveillance

循环肿瘤DNA多基因panel在非小细胞肺癌早期检测和疾病监测中的可行性

2025-10-100
OAAI
Design; Synthesis and Evaluation of Fluorescent Dihydropyridine-Dihydropyrimidinone Hybrids as Inducer of Cell-Cycle Arrest in Prostate Cancer Cell Line via Aurora Kinase interactions

设计;荧光二氢吡啶-二氢嘧啶酮杂合物的合成与评价:通过Aurora激酶相互作用诱导前列腺癌细胞系细胞周期停滞

2025-09-270
PRE
Establishment and molecular profiling of a PDX model of a metachronous brain tumor in a patient with constitutional mismatch repair deficiency with biallelic MSH6 variant

建立并分子表征了一例具有双等位基因MSH6变异的先天性错配修复缺陷患者的异时性脑瘤PDX模型。

2025-08-290
OAAI
Comprehensive microRNA expression analysis of pediatric gonadal germ cell tumors: unveiling novel biomarkers and signatures

小儿性腺生殖细胞肿瘤的综合microRNA表达分析: 揭示新的生物标志物和特征

2024-05-091
OA
HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer

HMGB1表达水平与非小细胞肺癌免疫治疗反应相关

2024-05-010
OAAI
Establishment and molecular characterization of HCB-541, a novel and aggressive human cutaneous squamous cell carcinoma cell line
2024-04-031
OAAI
Reproducibility of a 12-gene set for predicting outcome and benefit from ACT in earlystage NSCLC patients
2023-10-271
PRE
Potential New Therapeutic Approaches for Cisplatin-Resistant Testicular Germ Cell Tumors
2022-08-167
OA
Single nCounter assay for prediction of MYCN amplification and molecular classification of medulloblastomas: a multicentric study

用于预测髓母细胞瘤MYCN扩增和分子分类的单一nCounter分析: 多中心研究

2022-02-154
PRE